Paperonium

Health spending · Lancet Reg Health Am · 2024

The paper’s summary says Brazil’s lung-TB costs “exceeded $1.3 billion.” Its own results say $108 million.

The paper’s summaryover $1.3 billionHighest possible: 8 × the costliest year$171 million (a ceiling)The paper’s own results section$108 million, one-twelfth as much
The paper’s summaryover $1.3 billionHighest possible:8 × the costliest year$171 million (a ceiling)The paper’s ownresults section$108 million,one-twelfth as much

Total spent on lung TB, 2015–2022, US dollars; each square’s area matches its amount

The paper says

A study of what Brazil’s public health system spent treating lung tuberculosis (TB) from 2015 to 2022 says in its summary that the total “exceeded $1.3 billion” (US dollars). It repeats “approximately $1.3 billion” near the end of the paper.

Its own data show

In its results section, where it lays out the numbers in detail, the paper gives that same total (lung TB, 2015–2022, US dollars) as $108 million. Its costliest year was $21.4 million, so even eight such years make only $171 million. It also says $23.5 million went to patients treated for TB a second time.

Eight years can never cost more than eight times the costliest year, so $1.3 billion is impossible; the paper does not explain the gap. It is the summary’s headline number. Measured against $1.3 billion, the $23.5 million for second treatments looks like 2% of spending; measured against $108 million, it is more than a fifth.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Nationwide economic analysis of pulmonary tuberculosis in the Brazilian healthcare system over seven years (2015–2022): a population-based study · Lancet Reg Health Am (2024) · doi:10.1016/j.lana.2024.100905